Table 3.
Plasma concentrations of vitamins and metabolic markers (tHcy, Folate, Holo-TC, tCbl, MMA; mean ± SD) according to the MTHFR, TCN II, MTR and MTRR genotypes in the 9-yo group.
| 9-Year-Old | |||||
|---|---|---|---|---|---|
| SNP | tHcy (µmol/L) | Folate (nmol/L) | Holo-TC (pmol/L) | tCbl (pmol/L) | MMA (µmol/L) |
| MTHFR C677T | |||||
| CC | 3.7 ± 1.9 (n = 115) | 23.1 ± 9.0 (n = 109) | 101.8 ± 30.2 (n = 108) | 502.2 ± 156.3 (n = 110) | 0.274 ± 0.300 (n = 107) |
| CT | 3.7 ± 1.7 (n = 65) | 23.4 ± 9.7 (n = 60) | 100.0 ± 33.7 (n = 59) | 527.6 ± 178.6 (n = 63) | 0.270 ± 0.198 (n = 62) |
| TT | 4.5 ± 1.8 (n = 15) | 17.4 ± 7.1 (n = 14) | 92.7 ± 35.41 (n = 12) | 555.3 ± 176.2 (n = 14) | 0.295 ± 0.210 (n = 15) |
| MTHFR A1298C | |||||
| AA | 3.7 ± 1.8 (n = 101) | 23.4 ± 10.1 (n = 97) | 101.3 ± 33.7 (n = 93) | 511.1 ± 157.8 (n = 98) | 0.284 ± 0.252 (n = 97) |
| AC | 3.8 ± 1.8 (n = 59) | 22.1 ± 8.4 (n = 52) | 98.2 ± 27.2 (n = 53) | 544.5 ± 186.9 (n = 57) | 0.225 ± 0.599 (n = 56) |
| CC | 3.8 ± 2.0 (n = 35) | 22.1 ± 7.8 (n = 34) | 102.6 ± 33.0 (n = 33) | 472.9 ± 141.2 (n = 32) | 0.334 ± 0.448 (n = 31) |
| TCN2 A67G | |||||
| AA | 3.9 ± 1.8 (n = 146) | 22.8 ± 9.5 (n = 137) | 101.2 ± 29.9 (n = 117) | 523.0 ± 168.2 (n = 127) | 0.277 ± 0.238 (n = 139) |
| AG | 3.2 ± 2.0 (n = 37) | 22.1 ± 7.9 (n = 35) | 92.1 ± 26.4 (n = 33) | 489.8 ± 178.8 (n = 35) | 0.221 ± 0.054 (n = 35) |
| GG | 3.7 ± 2.4 (n = 5) | 26.1 ± 8.3 (n = 5) | 87.9 ± 40.6 (n = 3) | 561.2 ± 100.3 (n = 3) | 0.153 ± 0.043 (n = 4) |
| TCN2 C776G | |||||
| CC | 4.0 ± 1.8 (n = 59) | 22.5 ± 8.7 (n = 54) | 96.8 ± 29.2 (n = 48) | 496.8 ± 171.8 (n = 56) | 0.241 ± 0.063 (n = 55) |
| CG | 3.6 ± 1.9 (n = 74) | 21.5 ± 9.4 (n = 70) | 101.2 ± 29.8 (n = 64) | 525.1 ± 160.7 (n = 69) | 0.281 ± 0.306 (n = 70) |
| GG | 3.8 ± 2.0 (n = 42) | 23.8 ± 8.9 (n = 40) | 98.0 ± 29.7 (n = 61) | 529. 8 ± 182.1 (n = 40) | 0.287 ± 0.267 (n = 40) |
| MTR A2756G | |||||
| AA | 3.9 ± 1.5 (n = 70) | 23.8 ± 10.2 (n = 64) | 102.2 ± 25.4 (n = 63) | 538.9 ± 188.8 (n = 68) | 0.251 ± 0.084 (n = 67) |
| AG | 3.7 ± 1.7 (n = 44) | 23.6 ± 9.4 (n = 43) | 99.0 ± 33.7 (n = 44) | 531.0 ± 152.8 (n = 39) | 0.325 ± 0.403 (n = 42) |
| GG | 4.8 ± 3.3 (n = 2) | 21.7 ± 7.6 (n = 2) | 87.4 ± 28.2 (n = 2) | 467.7 ± 33.4 (n = 2) | 0.234 ± 0.044 (n = 2) |
| MTRR A66G | |||||
| AA | 3.9 ± 1.8 (n = 36) | 24.8 ± 9.8 (n = 33) | 109.0 ± 32.0 (n = 35) | 530.8 ± 180.8 (n = 34) | 0.257 ± 0.159 (n = 35) |
| AG | 3.8 ± 1.6 (n = 60) | 21.8 ± 9.1 (n = 55) | 100.4 ± 34.7 (n = 55) | 537.0 ± 165.7 (n = 56) | 0.262 ± 0.242 (n = 56) |
| GG | 4.0 ± 1.8 (n = 30) | 22.9 ± 9.1 (n = 27) | 100.4 ± 25.8 (n = 26) | 513.8 ± 183.8 (n = 28) | 0.354 ± 0.461 (n = 29) |
p values for differences between means of the three genotypes were tested with one-way analysis of variance (ANOVA). p values < 0.05 were considered statistically significant. No statistically significant differences were observed for any of the evaluated biomarkers among the different genotypes. Total Homocysteine (tHcy); total cobalamin (tCbl); holo-transcobalamin (Holo-TC); methylmalonic acid (MMA).